• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Study on biotransformation and pharmacokinetic of natural products

Study on biotransformation and pharmacokinetic of natural products

来源 :2013年第一届岭南国际DMPK论坛(The 1st Ling-nan International Forum on D | 被引量 : 0次 | 上传用户：mnbvcxzxzh
【摘 要】
：
Much more attention has been paid to Chinese herbal medicine as for new drug development.Natural products usually metabolize widely in vivo and their metabolic pathways are various and complicated.A p
【作 者】
：
王琰 
【机 构】
：
中国医学科学院 药物研究所
【出 处】
：
2013年第一届岭南国际DMPK论坛(The 1st Ling-nan International Forum on D
【发表日期】
：
2013年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Much more attention has been paid to Chinese herbal medicine as for new drug development.Natural products usually metabolize widely in vivo and their metabolic pathways are various and complicated.A possible reason is that one natural product with complicated structure and abundant functional groups would own many metabolic pathways.
其他文献
Mechanism-Based Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Perindopril in Spontan
The aim of the present study was to development a pharmacokinetic/pharmacodynamic (PK/PD) model for the characterization ofperindopril effect in spontaneously hypertensive rats (SHRs) while taking int
会议
A disease progression model for Alzheimer's disease
Background: The aim of this study was to establish a causal disease progression model quantifying the sequential change of biomarkers and their relative values as predictors of different Alzheimers Di
会议
Alzheimer's diseaseCSFAβ42p-tauhippocampus volumeclinical scoreNONMEM
Population Pharmacokinetics-pharmacodynamics modeling of risperidone and its active metabolite in Ch
Background: Risperidone, an anatypical antipsychotic agent, characterized as an antagonist of dopaminergic and serotonergic receptors, is now widely used in the treatment of patients with positive sym
会议
Application of Model-Based Methods to Characterize Exenatide-Loaded Double-Walled Microspheres: In V
Exenatide (glucagon-like-peptide-1 analogue) was authorized for marketing in the European Union in November 2006 and was approved by FDA in April 2005.To improve compliance, exenatide double-walled mi
会议
Personalized Medicine Based on the Population Pharmacokinetics of Valproic Acid in Children with Epi
Valproic acid (VPA) is an important drug in treatment of childhood epilepsy, however, VPA concentration should be monitored during epilepsy treatment.The aim of this study was to realize personalized
会议
Population Pharmacokinetics of Clozapine Conventional Tablets and Disintegrating Tablets in Chinese
Objevtive:To study the population pharmacokinetics of clozapine conventional tablets and disintegrating tablets in Chinese healthy volunteers.Methods:Fourty-two Chinese healthy volunteers were given 2
会议
clozapinedisintegrating tabletsHPLC-MS/MSpopulation pharmacokinetics
Power Analysis by Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Chinese
Objective:In vitro information on dextromethorphan (DXM) and the Advanced Dissolution Absorption Metabolism (ADAM) model, incorporated into PBPK simulator Simcyp(@) (v.12) were used to investigate dif
会议
Prediction of First-in-Human Dose of CPRC1 Using Allometric Scaling, IVIVE and PK/PD Modeling Method
Diabetes mellitus is one of the most common chronic disease in the world, CPRC 1 is a novel dipeptidylpeptidase-Ⅳ(DPP-4) inhibitor which was proposed to control hyperglycemia in patients with type 2 d
会议
Pharmacokinetic comparision of berberine in plasma after oral administration of pure berberine in no
In the present study, post inflammation irritable bowel syndrome(PI-IBS) rats were firsty established by intracolonic instillation of acetic acid with restraint stress.Then the pharmacokinetics of ber
会议
Dose finding of antofloxacinhydrochloride for treating bacterialinfectionsin early clinical trial fr
Aim: To find an appropriate dose regimen of antofloxacin, a concentration dependent antibacterial agent,for phase Ⅱ clinical trial through a population pharmacokinetic (PPK) study in healthy volunteer
会议